Literature DB >> 25151473

Key concepts in management of vulvar cancer.

Susan Zweizig1, Sharmilee Korets2, Joanna M Cain3.   

Abstract

Vulvar carcinoma is an uncommon tumor that is seen most often in older women. Subtle symptoms such as pruritus should prompt examination and targeted biopsy in all women as this disease can be successfully treated even in elderly, frail individuals. Vulvar cancer has a bimodal age distribution and is seen in both young and older women with risk factors including human papillomavirus (HPV) infection, smoking, and vulvar skin diseases (i.e., lichen sclerosus). This cancer is staged surgically, with an update in 2009 incorporating prognostic factors. The treatment of vulvar carcinoma has evolved to include more conservative surgical techniques that provide improved cure rates with emphasis on minimizing morbidity. Advanced and metastatic lesions are now treated with chemoradiation which produces substantial cure rates with decreased morbidity. Promising areas of research in vulvar cancer include refinement of sentinel lymph node biopsy, prevention of lymphedema, and preservation of sexual function following treatment.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HPV infection; chemoradiation; sentinel node; vulvar carcinoma; vulvar intraepithelial neoplasia

Mesh:

Year:  2014        PMID: 25151473     DOI: 10.1016/j.bpobgyn.2014.07.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  8 in total

Review 1.  Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

Authors:  Tommy R Buchanan; Whitney S Graybill; Jennifer Young Pierce
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  An Overview of Vulvar Cancer: A Single-Center Study from Northeast India.

Authors:  Megha Nandwani; D Barmon; Dimpy Begum; Haelom Liegise; A C Kataki
Journal:  J Obstet Gynaecol India       Date:  2019-08-16

3.  Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.

Authors:  Siqing Fu; Naiyi Shi; Jennifer Wheler; Aung Naing; Filip Janku; Sarina Piha-Paul; Jing Gong; David Hong; Apostolia Tsimberidou; Ralph Zinner; Vivek Subbiah; Ming-Mo Hou; Pedro Ramirez; Lois Ramondetta; Karen Lu; Funda Meric-Bernstam
Journal:  Gynecol Oncol Res Pract       Date:  2015-11-14

Review 4.  Essentiality of Trace Elements in Pregnancy, Fertility, and Gynecologic Cancers-A State-of-the-Art Review.

Authors:  James Curtis Dring; Alicja Forma; Zuzanna Chilimoniuk; Maciej Dobosz; Grzegorz Teresiński; Grzegorz Buszewicz; Jolanta Flieger; Tomasz Cywka; Jacek Januszewski; Jacek Baj
Journal:  Nutrients       Date:  2021-12-31       Impact factor: 5.717

5.  Study on the application and imaging characteristics of optical coherence tomography in vulva lesions.

Authors:  Lida Xu; Qian Ma; Shaochong Lin; Juan Ju; Shuo Feng; Zhongna Shi; Yang Bai; Junzhai Song; Junpeng Du; Baojin Wang
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

Review 6.  The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer.

Authors:  Andrea Giannini; Ottavia D'Oria; Benito Chiofalo; Valentina Bruno; Ermelinda Baiocco; Emanuela Mancini; Rosanna Mancari; Cristina Vincenzoni; Giuseppe Cutillo; Enrico Vizza
Journal:  J Obstet Gynaecol Res       Date:  2021-12-28       Impact factor: 1.697

Review 7.  Management of Early-Stage Vulvar Cancer.

Authors:  Priscila Grecca Pedrão; Yasmin Medeiros Guimarães; Luani Rezende Godoy; Júlio César Possati-Resende; Adriane Cristina Bovo; Carlos Eduardo Mattos Cunha Andrade; Adhemar Longatto-Filho; Ricardo Dos Reis
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

8.  Prevalence of human papillomavirus and its prognostic value in vulvar cancer: A systematic review and meta-analysis.

Authors:  Jianxin Zhang; Yang Zhang; Zhenyu Zhang
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.